New research from Moffitt Cancer Center demonstrates that RAS(ON) multi-selective inhibitors can directly block tumor growth while activating the immune system, offering the first targeted approach for patients with NRAS-mutant melanoma.
This aggressive form of skin cancer currently has limited treatment options beyond immune checkpoint inhibitors. The study, published in Cancer Immunology Research, reveals potential for durable responses, laying the groundwork for future clinical trials and a potential new standard of care.
Treatment Challenges in NRAS-Mutant Melanoma
Unlike BRAF-mutant melanoma patients who benefit from multiple FDA-approved targeted therapy combinations, NRAS-mutant disease patients lack such options. The current standard of care relies on immune checkpoint inhibitors, which work for some but not all patients. Many either don’t respond or eventually develop resistance.
“Treatment options are extremely limited for this group once immunotherapy stops working,” explained researchers. “Developing targeted therapies for NRAS-mutant melanoma has been a critical unmet need in the field.”
Novel Mechanism of Action
The investigational drug daraxonrasib (RMC-6236) and its preclinical counterpart RMC-7977 represent a new class of drugs designed to target the active “ON” form of RAS proteins – a goal researchers have pursued for decades.
By binding to active RAS proteins (NRAS, HRAS, and KRAS), these inhibitors block the downstream MAPK signaling pathway that drives tumor growth. This not only causes cancer cells to stop dividing and die but also makes tumors more visible to the immune system.
Critical Role of Immune Response
The immune system proved essential to the treatment response. RAS inhibitor treatment led to a surge in activated CD4+ and CD8+ T cells – key immune cells for recognizing and killing tumor cells – while reducing myeloid-derived suppressor cells that typically help tumors evade immunity.
In laboratory experiments, when these T cells were depleted, the drug could no longer eliminate tumors. “This tells us the drug works hand-in-hand with the body’s immune defenses to achieve durable responses,” researchers noted.
Promising Early Clinical Results
As part of early-phase clinical trials, two Moffitt patients with advanced NRAS-mutant melanoma received daraxonrasib treatment. One patient achieved a complete response (no detectable tumors on scans), while another showed partial response with significant tumor shrinkage.
“This is a landmark moment as it’s the first evidence that RAS inhibitors can work for this specific melanoma population,” researchers emphasized. “If these early findings hold in larger trials, this could represent the first targeted therapy developed specifically for NRAS-mutant melanoma.”
Next Steps and Future Development
Daraxonrasib is currently in phase 1 clinical trials focusing on establishing safety, tolerability, and optimal dosing. Following this phase, the drug will need to progress through phase 2 and 3 trials to evaluate efficacy in larger, more diverse patient populations.
Researchers cautiously optimistic: “While the early data is promising, confirming these results will take time. The next phases are crucial to verify the potential we’re seeing now for ultimately establishing a new standard of care.”
Related topics:
